|drug3525||Transpulmonary thermodilution Wiki||0.58|
|drug3193||Standard 12-lead ECG, NT-proBNP, echocardiography Wiki||0.58|
|D018754||Ventricular Dysfunction NIH||1.00|
|D018497||Ventricular Dysfunction, Right NIH||0.58|
|D006976||Hypertension, Pulmonary NIH||0.29|
There are 3 clinical trials
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.
Description: Body temperature(°C)Measure: Body temperature Time: Through study completion, an estimation of 6 months
Description: Blood pressure in mmHgMeasure: Blood pressure Time: Through study completion, an estimation of 6 months
Description: Pulse (heart rate) in times/minuteMeasure: Pulse (heart rate) Time: Through study completion, an estimation of 6 months
Description: Respiratory rate in times/minuteMeasure: Respiratory rate Time: Through study completion, an estimation of 6 months
Description: Cardiac index (L/min/m2)Measure: Data provided by transpulmonary thermodilution-CI Time: Through study completion, an estimation of 6 months
Description: Global end-diastolic volume(mL/m2)Measure: Data provided by transpulmonary thermodilution-GEDV Time: Through study completion, an estimation of 6 months
Description: Extravascular lung water (mL/kg)Measure: Data provided by transpulmonary thermodilution-EVLW Time: Through study completion, an estimation of 6 months
Description: Pulmonary vascular permeability indexMeasure: Data provided by transpulmonary thermodilution-PVPI Time: Through study completion, an estimation of 6 months
Description: Left ventricle ejection fraction, Segmental left ventricle contractility, Speckle tracking data of the left and right ventricles, Dimensions of right and left cavities and Diastolic function of left ventricleMeasure: Incidence of new-onset or reversible systolic left ventricular dysfunction Time: Through study completion, an estimation of 6 months
Description: The worst extravascular lung waterMeasure: Changes of extravascular lung water measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 months
Description: The worst pulmonary vascular permeability indexMeasure: Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 months
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has resulted in a pandemic of viral pneumonia. Substantial proportion of patients with COVID-19 have biochemical evidence of myocardial injuries during the acute phase. Possible mechanisms including acute coronary events, cytokine storm, and COVID-19 related myocarditis, have been postulated for the cardiac involvement in COVID-19. It is uncertain whether COVID-19 survivors are at risk cardiac dysfunction including cardiac arrhythmia and heart failure. The prospective screening study aims to evaluate the possible latent effects from COVID-19 in COVID-19 survivors. COVID-19 survivors 4-6 weeks after hospital discharge will be recruited from the Infectious Disease clinic, Queen Mary Hospital with standard 12-lead electrocardiogram, serum troponin, NT-proBNP, and standard transthoracic echocardiogram. The outcome measures include (1) new onset cardiac arrhythmia, (2) N Terminal (NT)-proBNP elevation above the diagnostic range of heart failure, and (3) newly detected left ventricular dysfunction.
Description: Atrial fibrillation, conduction blockMeasure: New-onset cardiac arrhythmia Time: At the time of screening
Description: Elevated NT-proBNP level above the age-specific diagnostic threshold of heart failureMeasure: Elevation of NT-proBNP Time: At the time of screening
Description: Left ventricular systolic functionMeasure: Left ventricular dysfunction Time: At the time of screening
Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.
Description: All cause deathMeasure: Mortality Time: 30 days
Description: Prevalence of left ventricular dysfunctionMeasure: Left ventricular dysfunction Time: Within 72 hours from admission
Description: Prevalence of right ventricular dysfunctionMeasure: Right ventricular dysfunction Time: Within 72 hours from admission
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports